Global CNS Therapeutics Market 2018-2022

HTF1203919

CNS therapeutics cater to CNS disorders that affect the structure or function of the brain or spinal cord such as Parkinson’s disease, epilepsy, Alzheimer’s disease, anxiety, depression, and bipolar disorders.

Technavio’s analysts forecast the Global CNS therapeutics market to grow at a CAGR of 4.36% during the period 2018-2022.

Covered in this report

The report covers the present scenario and the growth prospects of the CNS therapeutics market. To calculate the market size, the report considers the revenue generated from the sales of therapeutics for CNS disorders.

The market is divided into the following segments based on geography:

• Americas

• APAC

• EMEA

Technavio's report, Global CNS Therapeutics Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

• Eli Lilly

• F. Hoffmann-La Roche

• Johnson & Johnson

• Merck

• Novartis

Market driver

• Increasing prevalence of mental illness

• For a full, detailed list, view our report

Market challenge

• Side effects of CNS therapeutics

• For a full, detailed list, view our report

Market trend

• Increased adoption of new-generation drugs

• For a full, detailed list, view our report

Key questions answered in this report

• What will the market size be in 2022 and what will the growth rate be

• What are the key market trends

• What is driving this market

• What are the challenges to market growth

• Who are the key vendors in this market space

• What are the market opportunities and threats faced by the key vendors

• What are the strengths and weaknesses of the key vendors

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE

• Market ecosystem

• Market characteristics

• Market segmentation analysis

PART 05: MARKET SIZING

• Market definition

• Market sizing 2017

• Market size and forecast 2017-2022

PART 06: FIVE FORCES ANALYSIS

• Bargaining power of buyers

• Bargaining power of suppliers

• Threat of new entrants

• Threat of substitutes

• Threat of rivalry

• Market condition

PART 07: CUSTOMER LANDSCAPE

PART 08: MARKET SEGMENTATION BY END-USER

• Segmentation by end-user

• Comparison by end-user

• MHDs – Market size and forecast 2017-2022

• NDDs – Market size and forecast 2017-2022

• Others – Market size and forecast 2017-2022

• Market opportunity by end-user

PART 09: REGIONAL LANDSCAPE

• Geographical segmentation

• Regional comparison

• Americas – Market size and forecast 2017-2022

• EMEA – Market size and forecast 2017-2022

• APAC – Market size and forecast 2017-2022

• Key leading countries

• Market opportunity

PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES

• Market drivers

• Market challenges

PART 12: MARKET TRENDS

• Increasing awareness programs

• Increased adoption of new-generation drugs

• Advances in technology in treating mental disorders

PART 13: VENDOR LANDSCAPE

• Overview

• Landscape disruption

PART 14: VENDOR ANALYSIS

• Vendors covered

• Vendor classification

• Market positioning of vendors

• Eli Lilly

• F. Hoffmann-La Roche

• Johnson & Johnson

• Merck

• Novartis

PART 15: APPENDIX

• List of abbreviations

Exhibit 01: Parent market

Exhibit 02: Global healthcare market

Exhibit 03: Market characteristics

Exhibit 04: Market segments

Exhibit 05: Market definition - Inclusions and exclusions checklist

Exhibit 06: Market size 2017

Exhibit 07: Validation techniques employed for market sizing 2017

Exhibit 08: Global – Market size and forecast 2017-2022 ($ mn)

Exhibit 09: Global – Year-over-year growth 2018-2022 (%)

Exhibit 10: Five forces analysis 2017

Exhibit 11: Five forces analysis 2022

Exhibit 12: Bargaining power of buyers

Exhibit 13: Bargaining power of suppliers

Exhibit 14: Threat of new entrants

Exhibit 15: Threat of substitutes

Exhibit 16: Threat of rivalry

Exhibit 17: Market condition - Five forces 2017

Exhibit 18: Customer landscape

Exhibit 19: End-user – Market share 2017-2022 (%)

Exhibit 20: Comparison by end-user

Exhibit 21: MHDs – Market size and forecast 2017-2022 ($ mn)

Exhibit 22: MHDs – Year-over-year growth 2018-2022 (%)

Exhibit 23: NDDs – Market size and forecast 2017-2022 ($ mn)

Exhibit 24: NDDs – Year-over-year growth 2018-2022 (%)

Exhibit 25: Others – Market size and forecast 2017-2022 ($ mn)

Exhibit 26: Others – Year-over-year growth 2018-2022 (%)

Exhibit 27: Market opportunity by end-user

Exhibit 28: Global – Market share by geography 2017-2022 (%)

Exhibit 29: Regional comparison

Exhibit 30: Americas – Market size and forecast 2017-2022 ($ mn)

Exhibit 31: Americas – Year-over-year growth 2018-2022 (%)

Exhibit 32: EMEA – Market size and forecast 2017-2022 ($ mn)

Exhibit 33: EMEA – Year-over-year growth 2018-2022 (%)

Exhibit 34: APAC – Market size and forecast 2017-2022 ($ mn)

Exhibit 35: APAC – Year-over-year growth 2018-2022 (%)

Exhibit 36: Key leading countries

Exhibit 37: Market opportunity

Exhibit 38: Rise in population aged 65 and above (% of total)

Exhibit 39: Vendor landscape

Exhibit 40: Landscape disruption

Exhibit 41: Vendors covered

Exhibit 42: Vendor classification

Exhibit 43: Market positioning of vendors

Exhibit 44: Eli Lilly: Overview

Exhibit 45: Eli Lilly: Business segments

Exhibit 46: Eli Lilly: Organizational developments

Exhibit 47: Eli Lilly: Geographic focus

Exhibit 48: Eli Lilly– Segment focus

Exhibit 49: Eli Lilly: Key offerings

Exhibit 50: F. Hoffmann-La Roche overview

Exhibit 51: F. Hoffmann-La Roche– Business segments

Exhibit 52: F. Hoffmann-La Roche – Organizational developments

Exhibit 53: F. Hoffmann-La Roche– Geographic focus

Exhibit 54: F. Hoffmann-La Roche– Segment focus

Exhibit 55: F. Hoffmann-La Roche – Key offerings

Exhibit 56: Johnson & Johnson overview

Exhibit 57: Johnson & Johnson– Business segments

Exhibit 58: Johnson & Johnson– Organizational developments

Exhibit 59: Johnson & Johnson– Geographic focus

Exhibit 60: Johnson & Johnson– Segment focus

Exhibit 61: Johnson & Johnson– Key offerings

Exhibit 62: Merck: Overview

Exhibit 63: Merck: Business segments

Exhibit 64: Merck: Organizational developments

Exhibit 65: Merck: Geographic focus

Exhibit 66: Merck – Segment focus

Exhibit 67: Merck-Key offerings

Exhibit 68: Novartis: Overview

Exhibit 69: Novartis: Business segments

Exhibit 70: Novartis: Organizational developments

Exhibit 71: Novartis: Geographic focus

Exhibit 72: Novartis – Segment focus

Exhibit 73: Novartis-Key offerings

Make an enquiry before buying this Report

Format

Properties

1-User PDF

The report will be emailed to you. The report is sent in PDF format.

This is a single user license, allowing one specific user access to the report.

5-User PDF

The report will be emailed to you. The report is sent in PDF format.

This is a 1-5 user licence, allowing up to five users have access to the report.

Site PDF

The report will be emailed to you. The report is sent in PDF format.

This is a site license, allowing 1-10 employees within your organisation to access the report.

Enterprise PDF

The report will be emailed to you. The report is sent in PDF format.

This is an enterprise license, allowing all employees within your organisation to access the report.